The observed increased proportions of CD8+ T cells mid- and post-treatment would theoretically have positive clinical implications due to increased tumour killing by these cells [34]; however, post-treatment proportions of CD8+ (or CD4+) T cells or their fold change were not associated with improved survival. This evidence concerns the gene CD8A and neoplasm.